UPCOMING SESSIONS in ET
Fri, Nov 20, 2026
6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness Hamide Eygoren Register
UPCOMING SESSIONS in ET
Fri, Nov 20, 2026 · 6:00 – 7:00 AM Bangkok
Sadness, Anger and Fear: Coping With the Emotions of Illness
Hamide Eygoren
Register
View all sessions

Approval of Beyonttra in Brazil brings new treatment options for ATTR-CM

Source
Amyloidosis News Today

The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM).

The regulatory clearance from the Agência Nacional de Vigilância Sanitária “marks an important step forward for Brazilian patients living with ATTR-CM,” Jonathan Fox, MD, PhD, president and chief medical officer of the cardiovascular and renal diseases program at Bridgebio, the therapy’s developer, said in a company press release announcing the agency’s decision.

“[This] is a particularly meaningful advance for patients living in Brazil who have long faced limited options for this progressive, life-threatening disease,” Fox said.